330 related articles for article (PubMed ID: 34408825)
1. Dual inhibition of IL-17A and IL-17F in psoriatic disease.
Iznardo H; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211037846. PubMed ID: 34408825
[TBL] [Abstract][Full Text] [Related]
2. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
5. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
7. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
8. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
Chiricozzi A; De Simone C; Fossati B; Peris K
Psoriasis (Auckl); 2019; 9():29-35. PubMed ID: 31214486
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.
Kokolakis G; Ghoreschi K
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614836
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab: the new drug in the biologics armamentarium for psoriasis.
Freitas E; Torres T
Drugs Context; 2021; 10():. PubMed ID: 34178093
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.
Cole S; Manghera A; Burns L; Barrett J; Yager N; Rhys H; Skelton A; Cole J; Goodyear CS; Griffiths M; Baeten D; Bertolini M; Shaw S; Al-Mossawi H; Maroof A
J Allergy Clin Immunol; 2023 Sep; 152(3):783-798. PubMed ID: 37244461
[TBL] [Abstract][Full Text] [Related]
15. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab for the Treatment of Psoriasis.
Freitas E; Blauvelt A; Torres T
Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab: A Review in Psoriatic Arthritis.
Nie T; Shirley M
Drugs; 2024 May; 84(5):587-598. PubMed ID: 38703349
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
[TBL] [Abstract][Full Text] [Related]
20. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.
Navarro-Compán V; Puig L; Vidal S; Ramírez J; Llamas-Velasco M; Fernández-Carballido C; Almodóvar R; Pinto JA; Galíndez-Aguirregoikoa E; Zarco P; Joven B; Gratacós J; Juanola X; Blanco R; Arias-Santiago S; Sanz Sanz J; Queiro R; Cañete JD
Front Immunol; 2023; 14():1191782. PubMed ID: 37600764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
